Evaluating only Sleepio’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. That’s exactly how it died.
Key Events Timeline
FOUNDING
Sleepio/Big Health founded by Oxford sleep scientist Colin Espie and entrepreneur Peter Hames.
REGULATORY ACTION
FDA granted Breakthrough Device Designation for Sleepio as insomnia digital therapeutic, seen as major validation.
PIVOT
Shifted US strategy toward employer self-insured plans after insurer reimbursement pathway stalled repeatedly.
LAYOFF
Big Health laid off significant portion of US commercial team; Sleepio commercial scale-up effectively abandoned.
Full Analysis
Free · no account needed
Documented cause
Sleepio, a digital CBT-for-insomnia program developed by Oxford sleep scientist Colin Espie and acquired by Big Health in 2012, raised $75M total and obtained FDA Breakthrough Device designation in 2021. Despite clinical evidence, commercial adoption collapsed by 2023. Employers and insurers were unwilling to pay the premium pricing (~$300 per user) without mandated coverage. Big Health conducted substantial layoffs in 2023 as the US commercial market failed to materialize at scale. The NHS partnership provided credibility but not commercial viability.
Lesson
“Clinical evidence is necessary but insufficient; lack of mandated insurance reimbursement kills even gold-standard digital therapeutics.”